Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Stomach Neoplasms × pertuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 41 Ovarian Neoplasms 4 Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Solid Tumor 2 Rectal Neoplasms 2 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Inflammatory Breast Neoplasms 2 HER2-positive Breast Cancer 2 Colonic Neoplasms 2 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Patient Preference 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Neoplasms, Unknown Primary 1 Multiple Endocrine Neoplasia 1 Malignant Solid Neoplasm 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 Her2-Positive Breast Cancer 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Early Breast Cancer 1 Fallopian Tube Neoplasms 1 Carcinoma, Neuroendocrine 1 Carcinoid Tumor 1 Breast Neoplasms, Male 1 Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 47 Cisplatin 43 Fluorouracil 42 Capecitabine 41 pembrolizumab 31 Leucovorin 28 Docetaxel 22 Irinotecan 19 Paclitaxel 18 Trastuzumab 17 Bevacizumab 12 Ramucirumab 11 Cetuximab 9 Radiotherapy 8 Surgical Procedures, Operative 7 Nivolumab 7 S 1 (combination) 6 Epirubicin 6 Carboplatin 6 Sunitinib 4 Platinum 4 Mitomycin 4 trastuzumab deruxtecan 3 olaparib 3 epacadostat 3 bemarituzumab 3 Pemetrexed 3 Ipilimumab 3 Folfox protocol 3 Everolimus 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01461057 2018-08-09

JOSHUA

Hoffmann-La Roche

Phase 2 Completed

30 enrolled 9 charts

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡